Janux Therapeutics

Yahoo Finance • 4 days ago

Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence

(RTTNews) - Janux Therapeutics, Inc. (JANX), a clinical-stage biopharmaceutical company, provided an update that the Phase 1a dose-escalation portion of the ongoing Phase 1 study evaluating JANX008 across multiple solid tumour indications... Full story

Yahoo Finance • 4 days ago

Here are the most and least likely M&A targets in biotech, according to Truist

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly o... Full story

Yahoo Finance • 22 days ago

Do JANX007’s Interim Results Put Janux Therapeutics’ (JANX) TRACTr Platform Competitiveness to the Test?

In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in 30% of evaluable patients and radiograph... Full story

Yahoo Finance • 25 days ago

Stocks making the biggest moves midday: Maplebear, Boeing, Credo Technology, XPO, MongoDB & more

Check out the companies making the biggest moves midday: Maplebear — The parent company of Instacart fell nearly 4% after Amazon said it's testing "ultra-fast" delivery of groceries in Seattle and Philadelphia. These deliveries take about... Full story

Yahoo Finance • 26 days ago

Stocks making the biggest moves premarket: MongoDB, Strategy, Signet Jewelers, Credo and more

Check out the companies making the biggest moves in premarket trading: MongoDB — Shares of the developer data platform soared 24% following strong third-quarter results. Adjusted earnings were $1.32 per share on revenue of $628 million, co... Full story

Yahoo Finance • 26 days ago

Biggest stock movers Tuesday: CRDO, MDB, and more

[Financial asset invest analysis with volume and candle stick chart] TERADAT SANTIVIVUT Stock futures were slightly up in the premarket hours of Tuesday amid a Bitcoin price decline and rising anticipation for a Federal Reserve interest r... Full story

Yahoo Finance • 26 days ago

Janux reports positive phase 1 results for JANX007 in mCRPC; stock down

[Close-Up Shot of Scientists Hands typing Data in Laptop in Laboratory] Tom Werner Janux Therapeutics (JANX [https://seekingalpha.com/symbol/JANX]) on late Monday reported [https://seekingalpha.com/pr/20324271-janux-announces-encouraging-... Full story

Yahoo Finance • 3 months ago

Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential. On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target. Truist believes that the co... Full story

Yahoo Finance • 4 months ago

Janux is a new Buy at Truist ahead of catalyst rich H2

[Usa ready for a stock market crash] franckreporter Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX [https://seekingalpha.com/symbol/JANX]) with a Buy recommendation and a $100 target on Wednesday, citing a cata... Full story

Yahoo Finance • 4 months ago

Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration

Janux Therapeutics Inc. (NASDAQ:JANX) is one of the best small cap stocks with biggest upside potential. On August 5, Janux Therapeutics announced a clinical milestone in its collaboration with Merck & Co. Inc. (NYSE:MRK), with the first p... Full story

Yahoo Finance • 5 months ago

Janux Therapeutics stock hits 52-week low at 22.25 USD

Janux Therapeutics Inc. reached a new 52-week low, with its stock price falling to 22.25 USD. This recent dip underscores a challenging year for the biotechnology company, which has seen its stock value decline by 37.03% over the past 12 m... Full story

Yahoo Finance • 5 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

R&D Day highlighted TRACTr, TRACIr, and ARM pipeline progress and best-in-class potential of novel bispecific ARM platform for autoimmune diseases Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the se... Full story

Yahoo Finance • 5 months ago

The Math Shows SCHA Can Go To $31

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

First patient dosed in the lead collaboration program triggers a $10 million milestone payment to Janux SAN DIEGO, August 05, 2025--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical compa... Full story

Yahoo Finance • 6 months ago

Janux Therapeutics reports annual meeting results

On June 11, 2025, Janux Therapeutics, Inc., a biotechnology company currently valued at $1.48 billion, conducted its 2025 Annual Meeting of Stockholders. The meeting occurred amid challenging market conditions, with the stock down over 58%... Full story

Yahoo Finance • 7 months ago

SA Asks: Which oncology companies are attractive M&A targets?

[word m and a made with wood building blocks, stock image] Maksim Labkouski Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor [https://seekingalpha.com/author/biocgt-investor],... Full story

Yahoo Finance • 8 months ago

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential

We recently published a list of Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other unknown billionai... Full story

Yahoo Finance • 8 months ago

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other top small cap stocks to buy wit... Full story

Yahoo Finance • 9 months ago

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

We recently published a list of the 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Janux Therapeutics Inc. (NASDAQ:JANX) stands against other up and coming stock... Full story

Yahoo Finance • last year

Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Janux Therapeutics Inc. (NASDAQ:JANX) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps... Full story